Archive

Posts Tagged ‘suvorexant’

Dr. Steve Dingman: FDA Comments on Insomnia Medication’s Safety

In his role as drug safety physician, Dr. Steve Dingman assists UBC, Inc., with global clinical safety matters. Dr. Steve Dingman works with the company’s clinical sub and product lifecycle teams. He is a graduate of the University of North Carolina at Chapel Hill.

The U.S. Food and Drug Administration (FDA) recently determined that suvorexant, an experimental insomnia medication, is safe only at lower doses than those originally proposed. The drug was designed to treat insomnia by inhibiting wakefulness.

The pharmaceutical company that created the drug developed the medication to compete with common sleep aids like Lunesta and Ambien. If approved, analysts predict that suvorexant will bring revenues in the hundreds of millions of dollars.

Suvorexant works by interfering with orexin, a neurotransmitter that causes wakeful and aroused states. By blocking the neurotransmitter, the drug treats insomnia without the next-morning side effects commonly caused by current insomnia medications on the market.

Advertisements